Oncostem Biotherapeutics LLC is categorized under Commercial Biotechnical Research in Philadelphia, PA and active since 2012.
Oncostem Biotherapeutics LLC was established in 2012, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Rudolph Willis at the company’s single location by writing to 2200 Arch St Unit 712, Philadelphia, Pennsylvania PA 19103 or by phoning (267) 886-8339. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Oncostem Biotherapeutics LLC |
| Contact Person: | Rudolph Willis |
| Address: | 2200 Arch St Unit 712, Philadelphia, Pennsylvania 19103 |
| Phone Number: | (267) 886-8339 |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Oncostem Biotherapeutics LLC was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact Rudolph Willis for inquiries that concern Oncostem Biotherapeutics LLC by calling the company number (267) 886-8339, as your correspondence is most welcome. Additionally, the physical location of the single location of Oncostem Biotherapeutics LLC can be found at the coordinates 39.955919,-75.176515 as well as the street address 2200 Arch St Unit 712 in Philadelphia, Pennsylvania 19103.
For its online presence, you may visit Oncostem Biotherapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.